<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PEN</journal-id>
<journal-id journal-id-type="hwp">sppen</journal-id>
<journal-id journal-id-type="nlm-ta">JPEN J Parenter Enteral Nutr</journal-id>
<journal-title>Journal of Parenteral and Enteral Nutrition</journal-title>
<issn pub-type="ppub">0148-6071</issn>
<issn pub-type="epub">1941-2444</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0148607111414580</article-id>
<article-id pub-id-type="publisher-id">10.1177_0148607111414580</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Communications</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Docosahexaenoic Acid and Arachidonic Acid Prevent Essential Fatty Acid Deficiency and Hepatic Steatosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Le</surname><given-names>Hau D.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0148607111414580">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Meisel</surname><given-names>Jonathan A.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0148607111414580">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>de Meijer</surname><given-names>Vincent E.</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0148607111414580">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fallon</surname><given-names>Erica M.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0148607111414580">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gura</surname><given-names>Kathleen M.</given-names></name>
<degrees>PharmD</degrees>
<xref ref-type="aff" rid="aff2-0148607111414580">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nose</surname><given-names>Vania</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff3-0148607111414580">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bistrian</surname><given-names>Bruce R.</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff4-0148607111414580">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Puder</surname><given-names>Mark</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0148607111414580">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0148607111414580"><label>1</label>Department of Surgery and the Vascular Biology Program, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts</aff>
<aff id="aff2-0148607111414580"><label>2</label>Department of Pharmacy, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts</aff>
<aff id="aff3-0148607111414580"><label>3</label>Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts</aff>
<aff id="aff4-0148607111414580"><label>4</label>Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts</aff>
<author-notes>
<corresp id="corresp1-0148607111414580">Mark Puder, MD, PhD, 300 Longwood Avenue, Fegan 3, Boston, MA 02115; e-mail: <email>mark.puder@childrens.harvard.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2012</year>
</pub-date>
<volume>36</volume>
<issue>4</issue>
<fpage>431</fpage>
<lpage>441</lpage>
<history>
<date date-type="received">
<day>20</day>
<month>3</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>5</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p><italic>Objectives</italic>: Essential fatty acids are important for growth, development, and physiologic function. α-Linolenic acid and linoleic acid are the precursors of docosahexaenoic and arachidonic acid, respectively, and have traditionally been considered the essential fatty acids. However, the authors hypothesized that docosahexaenoic acid and arachidonic acid can function as the essential fatty acids. <italic>Methods</italic>: Using a murine model of essential fatty acid deficiency and consequent hepatic steatosis, the authors provided mice with varying amounts of docosahexaenoic and arachidonic acids to determine whether exclusive supplementation of docosahexaenoic and arachidonic acids could prevent essential fatty acid deficiency and inhibit or attenuate hepatic steatosis. <italic>Results</italic>: Mice supplemented with docosahexaenoic and arachidonic acids at 2.1% or 4.2% of their calories for 19 days had normal liver histology and no biochemical evidence of essential fatty acid deficiency, which persisted when observed after 9 weeks. <italic>Conclusion</italic>: Supplementation of sufficient amounts of docosahexaenoic and arachidonic acids alone without α-linolenic and linoleic acids meets essential fatty acid requirements and prevents hepatic steatosis in a murine model.</p>
</abstract>
<kwd-group>
<kwd>α-linolenic acid</kwd>
<kwd>linoleic acid</kwd>
<kwd>ω-3 fatty acid</kwd>
<kwd>ω-6</kwd>
<kwd>fatty liver</kwd>
<kwd>polyunsaturated fatty acids</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0148607111414580">
<title>Clinical Relevancy Statement</title>
<p>We found that docosahexaenoic acid (DHA) and arachidonic acid (AA) alone without the traditional essential fatty acids (EFAs) α-linolenic acid (ALA) and linoleic acid (LA) meet EFA requirements and prevent hepatic steatosis. This suggests that DHA and AA can be considered EFAs. Traditional thinking is that patients have to receive adequate ALA and LA to meet EFA requirements. With this finding, new parenteral and enteral formulas can be developed on the basis of these 2 fatty acids to take advantage of their metabolically active properties without fear of clinical or biochemical essential fatty deficiency.</p>
</sec>
<sec id="section2-0148607111414580" sec-type="intro">
<title>Introduction</title>
<p>EFAs are polyunsaturated fatty acids (PUFAs) that are required nutrients for growth, development, and other important physiologic functions. EFAs are termed as such because they must be acquired through dietary sources, as mammals cannot synthesize them from simple carbon precursors or interconvert other fatty acids. When less than 1%−2% of total calories are provided from EFAs,<sup><xref ref-type="bibr" rid="bibr1-0148607111414580">1</xref></sup> EFA deficiency (EFAD) typically occurs.</p>
<p>There are 3 major families of PUFAs: ω-3, ω-6, and ω-9, all of which are metabolized using the same group of enzymes. Traditionally, ALA (ω-3) and LA (ω-6) are considered the only EFAs.<sup><xref ref-type="bibr" rid="bibr2-0148607111414580">2</xref>,<xref ref-type="bibr" rid="bibr3-0148607111414580">3</xref></sup> Their downstream products include the highly physiologically relevant eicosapentaenoic acid (EPA; ω-3), DHA (ω-3), and AA (ω-6). These are considered critical metabolites, as EPA and AA are important precursors to eicosanoids, including prostaglandins, thromboxanes, prostacyclins, and leukotrienes, which mediate numerous physiologic and biochemical processes. EPA and DHA are important for optimal visual and cognitive function,<sup><xref ref-type="bibr" rid="bibr4-0148607111414580">4</xref></sup> in addition to providing the source of anti-inflammatory metabolites and promoting resolution of the inflammatory process.<sup><xref ref-type="bibr" rid="bibr5-0148607111414580">5</xref></sup></p>
<p>When provided as the sole source of fat, a fish oil–based lipid emulsion has been reported to be effective in treating EFAD and reversing cholestasis.<sup><xref ref-type="bibr" rid="bibr6-0148607111414580">6</xref></sup> In addition, a fish oil–based diet with more than 13% of the total calories from fish oil prevents EFAD and maintains growth in a murine model.<sup><xref ref-type="bibr" rid="bibr7-0148607111414580">7</xref></sup> Since DHA and AA represent the principally active ω-3 and ω-6 fatty acids in fish oil, we hypothesize that DHA and AA will prevent EFAD and the resultant hepatic steatosis, as well as provide ample amounts of EPA in a murine model of hepatic steatosis.</p>
</sec>
<sec id="section3-0148607111414580" sec-type="methods">
<title>Experimental Procedures</title>
<sec id="section4-0148607111414580">
<title>Animal Model: Hepatic Steatosis and Biochemical Model of EFAD</title>
<p>Experiments were performed on 4- to 6-week-old C57Bl6 mice (Jackson Laboratories, Bar Harbor, ME). The animals were housed in a barrier room with a 12-hour light cycle and were acclimated to their environment for at least 72 hours before initiation of the experiment. Experimental mice were housed in groups of 5 and fed an ad libitum liquid, fat-free, high-carbohydrate diet (HCD), similar to the parenteral nutrition used clinically at Boston Children’s Hospital. The HCD contained 20% dextrose, a mixture of 2% essential and nonessential amino acids (TrophAmine, B Braun Medical, Bethleham, PA), 30 mEq/L sodium, 20 mEq/L potassium, 15 mEq/L calcium (as gluconate), 10 mEq/L magnesium, 10 mM phosphate, 5 mEq/L acetate, 30 mEq/L chloride, 0.2% pediatric trace elements (American Reagent, Shirley, NY), and 0.5% pediatric multivitamins (Hospira, North Chicago, IL). The mice were kept on this diet for 19 days, a duration known to cause severe hepatic steatosis.<sup><xref ref-type="bibr" rid="bibr8-0148607111414580">8</xref></sup> In the long-term study, animals received this diet for 9 weeks. Control animals were fed the standard AIN-93M purified rodent diet (Dyets Inc, Bethlehem, PA), containing 140 g/kg casein, 1.8 g/kg L-cystine, 100 g/kg sucrose, 465.9 g/kg cornstarch, 155 g/kg dextrose, 40 g/kg soybean oil, 0.8 mg/kg t-butylhydroquinone, 50 g/kg cellulose, 35 g/kg mineral mix, 10 g/kg vitamin mix, and 2.5 g/kg choline bitartrate. The fatty acid composition of the soybean oil included 6.42% ALA (18:3 n-3), 51.3% LA (18:2 n-6), 21.9% oleic acid (18:1 n-9), 10% palmitic acid (16:0), 3.9% stearic acid (18:0), 0.29% arachidic acid (20:0), and 0.32% behenic acid (22:0). Animals also had access to water ad libitum.</p>
<p>Animal protocols complied with the National Institutes of Health’s Animal Research Advisory Committee guidelines and were approved by the Boston Children’s Hospital Animal Care and Use Committee.</p>
</sec>
<sec id="section5-0148607111414580">
<title>Treatment</title>
<p>Hydrogenated coconut oil (HCO) and AA (98% grade) were purchased from Cayman Chemical (Ann Arbor, MI). DHA (87.4% DHA, 12.6% sterols) was provided by Martek (Columbia, MD). A 19-day experiment was conducted on 6 groups of mice (n = 5 in each); another 3 groups (n = 5 in each) were used in a 9-week experiment to test the long-term effects. In the 19-day experiment, mice were fed both a fat-free liquid diet (HCD-only) and an EFA-deficient liquid diet (HCD-0) to create EFAD. In both experiments, mice on the HCD (except HCD-only) also received a daily lipid mixture equivalent to 5% of their daily caloric intake via orogastric gavage. The groups are outlined in <xref ref-type="table" rid="table1-0148607111414580">Table 1</xref>. The lipid mixture comprised HCO, DHA, and AA. In the 19-day experiment, the supplemented lipid mixture had a DHA:AA ratio of 20:1 and provided daily caloric intake in the amount of 0% (HCD-0), 0.21% (HCD-0.21), 2.1% (HCD-2.1), or 4.2% (HCD-4.2). The amount of PUFAs in the fish oil–based lipid emulsion previously used fluctuates in its composition at approximately 14.4%−30.9% DHA, 12.5%−28.2% EPA, 1%−4% AA, 0.1%−0.7% LA, and &lt; 0.2% ALA.<sup><xref ref-type="bibr" rid="bibr9-0148607111414580">9</xref></sup> Based on these data, the ratio of DHA:AA could range 3.6:1–30.9:1. We chose the DHA:AA ratio of 20:1 for this experiment. HCO, which contains trace amounts of PUFAs, was added to bring the total fat calories of the mixtures to 5% in the high-carbohydrate, lipid-containing diets. The 9-week experiment comprised a control group, an HCD-0L group, and an HCD-2.1L group. The HCD-2.1L group was selected on the basis of the results from the 19-day experiment.</p>
<table-wrap id="table1-0148607111414580" position="float">
<label>Table 1.</label>
<caption>
<p>Percentage of Hydrogenated Coconut Oil, Docosahexaenoic Acid, and Arachidonic Acid in Each Lipid Mixture</p>
</caption>
<graphic alternate-form-of="table1-0148607111414580" xlink:href="10.1177_0148607111414580-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Group<sup><xref ref-type="table-fn" rid="table-fn2-0148607111414580">a</xref></sup></th>
<th align="center">Hydrogenated Coconut Oil</th>
<th align="center">Docosahexaenoic Acid</th>
<th align="center">Arachidonic Acid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td align="center">—</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td>HCD-only</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>HCD-0 / HCD-0L</td>
<td>5.00</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>HCD-0.21</td>
<td>4.79</td>
<td>0.20</td>
<td>0.01</td>
</tr>
<tr>
<td>HCD-2.1 / HCD-2.1L</td>
<td>2.90</td>
<td>2.00</td>
<td>0.10</td>
</tr>
<tr>
<td>HCD-4.2</td>
<td>0.80</td>
<td>4.00</td>
<td>0.20</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0148607111414580">
<p>HCD, high-carbohydrate diet.</p>
</fn>
<fn id="table-fn2-0148607111414580">
<label>a</label>
<p>The 19-day experiment had 6 groups: control, HCD-only, HCD-0, HCD-0.21, HCD-2.1, and HCD-4.2. The 9-week experiment had 3 groups: control, HCD-0L, and HCD-2.1L. The total fat in each lipid mixture provided 5% of the daily caloric intake.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section6-0148607111414580">
<title>Measurement of Serum Liver Enzymes</title>
<p>At the end of each experiment, mice were fasted for 4 hours and then anesthetized with 300 µl of 2.5% Tribromoethanol (Sigma-Aldrich Corporation, St Louis, MO) via intraperitoneal injection. Approximately 600 µl of blood was then collected from each mouse via retro-orbital puncture and centrifuged at 4°C at 1,000 <italic>g</italic> for 10 minutes. The serum was aspirated, and about 100 µl was brought to the Clinical Laboratory at Boston Children’s Hospital for measurement of alanine aminotransferase (ALT). The remaining serum was stored at −80°C and used for serum fatty acid analysis.</p>
</sec>
<sec id="section7-0148607111414580">
<title>Histologic Evaluation and Degree of Steatosis</title>
<p>Mice were euthanized and their livers excised. A designated lobe of the liver was fixed in 10% formalin overnight, washed with chilled phosphate buffered saline solution, and embedded in paraffin. The specimens were then sliced and stained with hematoxylin and eosin. The remaining portion of liver was immediately snap-frozen in liquid nitrogen and used for liver fatty acid analysis.</p>
<p>Histologic analysis was performed on hematoxylin and eosin sections by an experienced pathologist in a blinded fashion. The degree of steatosis was graded on the basis of an established system.<sup><xref ref-type="bibr" rid="bibr10-0148607111414580">10</xref></sup> Macrovesicular steatosis was graded on a 0–3 scale based on the percentage of hepatocytes affected in each specimen: 0, none; 1, &lt; 33%; 2, 33%−66%; 3, &gt; 66%. Data were expressed as median with interquartile range (IQR).</p>
</sec>
<sec id="section8-0148607111414580">
<title>Analysis of Serum and Liver Fatty Acid Composition</title>
<p>Serum and liver samples were prepared and the total lipids extracted on the basis of methods from Folch et al.<sup><xref ref-type="bibr" rid="bibr11-0148607111414580">11</xref></sup> Briefly, chloroform and methanol (Fisher, Fair Lawn, NJ) were added at a ratio of 2:1, followed by a potassium chloride (Aldrich, Milwaukee, WI) salt wash to isolate the total lipid fraction. Plasma total lipids were extracted from 40–150 µl of plasma. Tricosanoic free fatty acid (Sigma, St Louis, MO) was added to each sample as an internal standard. The plasma and liver total lipids were saponified with 0.5 N of methanolic sodium hydroxide (Sigma) and the fatty acids converted to methyl esters with 14% BF<sub>3</sub>/methanol (Sigma-Aldrich) at 100°C for 30 minutes.<sup><xref ref-type="bibr" rid="bibr12-0148607111414580">12</xref></sup> Butylated hydroxytoluene (Sigma-Aldrich) was added before saponification, and all samples were purged with N<sub>2</sub> throughout the process to minimize oxidation.</p>
<p>Fatty acid methyl esters were analyzed by gas liquid chromatography using a Hewlett Packard 6890 equipped with a flame ionization detector. Peaks were identified by comparison of retention times with external fatty acid methyl ester standard mixtures from NuCheck Prep (Elysian, MN). The fatty acid profiles were expressed as percentage of the total fatty acid (weight percentage).</p>
</sec>
<sec id="section9-0148607111414580">
<title>Determination of EFAD</title>
<p>The triene-tetraene (T:T) ratio is a biochemical marker used to characterize EFAD, as determined when the ratio of serum Mead acid (20:3 n-9) to AA (20:4 n-6) is greater than 0.2. Another marker of EFAD is the EFA index, defined as the (n-3 + n-6):(n-7 + n-9) ratio. These ratios are widely accepted biochemical markers to diagnose EFAD in animals<sup><xref ref-type="bibr" rid="bibr7-0148607111414580">7</xref>,<xref ref-type="bibr" rid="bibr13-0148607111414580">13</xref>,<xref ref-type="bibr" rid="bibr14-0148607111414580">14</xref></sup> and humans.<sup><xref ref-type="bibr" rid="bibr6-0148607111414580">6</xref>,<xref ref-type="bibr" rid="bibr15-0148607111414580">15</xref></sup></p>
</sec>
<sec id="section10-0148607111414580">
<title>Statistical Analysis</title>
<p>The group means were compared with analysis of variance for differences with post hoc analysis based on Tukey test. For nonparametric data, group medians were compared with the Kruskal-Wallis test. <italic>P</italic> &lt; .05 was considered statistically significant. All statistical tests were performed with SPSS 17.0 (SPSS Inc, Chicago, IL) and figures created with Prism 5.01 (GraphPad Software Inc, La Jolla, CA). Steatosis scores are reported as medians (IQR). Other data are expressed as mean ± SD.</p>
</sec>
</sec>
<sec id="section11-0148607111414580" sec-type="results">
<title>Results</title>
<sec id="section12-0148607111414580">
<title>Animal Outcome</title>
<p>All animals survived to completion of the study. The growth curves of the 19-day and 9-week experiments are shown in <xref ref-type="fig" rid="fig1-0148607111414580">Figure 1</xref>. In the 19-day experiment (<xref ref-type="fig" rid="fig1-0148607111414580">Figure 1A</xref>), HCD-4.2 mice experienced weight loss in the first week, although animals had appropriate weight gain after 19 days. This effect was thought to be due to toxicity of AA.<sup><xref ref-type="bibr" rid="bibr16-0148607111414580">16</xref>,<xref ref-type="bibr" rid="bibr17-0148607111414580">17</xref></sup> There were no statistically significant differences in body weight gain among groups during the study. Since mice in the HCD-4.2 group experienced weight loss in the first week, we decided to eliminate this group from the long-term experiment. In the 9-week experiment, there were no statistically significant differences in percentage body weight gain among the 3 groups (<xref ref-type="fig" rid="fig1-0148607111414580">Figure 1B</xref>). Mice in the control, HCD-0L, and HCD-2.1L groups gained 51%, 50%, and 52% of their weight, respectively. None of the mice developed dermatitis or alopecia, the hallmark clinical signs of EFAD.</p>
<fig id="fig1-0148607111414580" position="float">
<label>Figure 1.</label>
<caption>
<p>Growth curves of mice in the 19-day and 9-week experiments. (A) In the 19-day experiment, mice received a supplemented lipid mixture with a DHA:AA ratio of 20:1, which provided 0% (HCD-0), 0.21% (HCD-0.21), 2.1% (HCD-2.1), or 4.2% (HCD-4.2) of their daily caloric intake. Control mice received the standard AIN-93M purified rodent diet. (B) In the 9-week experiment, mice received a lipid mixture that provided 0% (HCD-0L) or 2.1% (HCD-2.1L) of their daily caloric intake. Mice in HCD-4.2 group experienced weight loss in the first week of treatment but caught up by day 14. There was no difference in the mean body weight or the percentage of body weight gain among the groups by the end of the experiment. Data are shown as mean body weight ± SD.</p>
<p>AA, arachidonic acid; DHA, docosahexaenoic acid; HCD, high-carbohydrate diet.</p>
</caption>
<graphic xlink:href="10.1177_0148607111414580-fig1.tif"/>
</fig>
</sec>
<sec id="section13-0148607111414580">
<title>Fatty Acid Analysis</title>
<sec id="section14-0148607111414580">
<title>ALA and LA</title>
<p>ALA (18:3 n-3) and LA (18:2 n-6) are considered to be the 2 EFAs. Their levels in all the treated groups compared to the control group were significantly lower in serum and liver (<xref ref-type="table" rid="table2-0148607111414580">Tables 2</xref> and <xref ref-type="table" rid="table3-0148607111414580">3</xref>). Interestingly, serum LA levels were also significantly lower in HCD-2.1 and HCD-4.2 groups compared to the EFA-deficient mice (HCD-0 group).</p>
<table-wrap id="table2-0148607111414580" position="float">
<label>Table 2.</label>
<caption>
<p>Fatty Acid Composition of Serum and Liver in the 19-Day Experiment<sup><xref ref-type="table-fn" rid="table-fn4-0148607111414580">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table2-0148607111414580" xlink:href="10.1177_0148607111414580-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Mole, %</th>
<th align="center">Control</th>
<th align="center">HCD-Only</th>
<th align="center">HCD-0</th>
<th align="center">HCD-0.21</th>
<th align="center">HCD-2.1</th>
<th align="center">HCD-4.2</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="7">Serum</td>
</tr>
<tr>
<td> 16:0</td>
<td>17.54 ± 1.51</td>
<td>19.77 ± 0.65</td>
<td>19.88 ± 0.78</td>
<td>21.86 ± 1.60<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>23.55 ± 2.10<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>23.10 ± 0.47<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 16:1 n-7</td>
<td>2.17 ± 0.24</td>
<td>4.99 ± 0.46<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>5.71 ± 0.37<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>5.95 ± 0.88<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>5.05 ± 0.51<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>4.32 ± 0.36<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 18:0</td>
<td>11.75 ± 1.06</td>
<td>10.51 ± 0.61</td>
<td>10.28 ± 1.04</td>
<td>11.31 ± 0.96</td>
<td>11.19 ± 1.94</td>
<td>11.67 ± 0.91</td>
</tr>
<tr>
<td> 18:1 n-9</td>
<td>15.79 ± 2.37</td>
<td>24.54 ± 1.17<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>26.33 ± 3.85<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>26.41 ± 2.39<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>22.70 ± 5.16<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>16.49 ± 3.93</td>
</tr>
<tr>
<td> 18:1 n-7</td>
<td>3.28 ± 0.34</td>
<td>5.26 ± 0.84<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>5.17 ± 1.00<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>5.11 ± 0.47<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>2.67 ± 1.19<sup><xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>1.42 ± 0.37<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 18:2 n-6</td>
<td>24.25 ± 1.03</td>
<td>4.70 ± 0.50<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>5.73 ± 2.08<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>5.98 ± 0.83<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>2.96 ± 0.72<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>2.54 ± 0.80<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 18:3 n-6</td>
<td>0.18 ± 0.02</td>
<td>0.20 ± 0.03</td>
<td>0.23 ± 0.07</td>
<td>0.14 ± 0.01<sup><xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>0.03 ± 0.03<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>0.03 ± 0.02<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 18:3 n-3</td>
<td>0.32 ± 0.06</td>
<td>0.05 ± 0.01<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.07 ± 0.03<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.06 ± 0.03<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.09 ± 0.03<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.10 ± 0.01<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
</tr>
<tr>
<td> 20:3 n-9</td>
<td>0.41 ± 0.21</td>
<td>8.53 ± 1.58<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>6.92 ± 1.82<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>2.73 ± 0.99<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>0.18 ± 0.20<sup><xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>0.01 ± 0.02<sup><xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 20:3 n-6</td>
<td>1.64 ± 0.25</td>
<td>1.68 ± 0.19</td>
<td>1.77 ± 0.36</td>
<td>1.29 ± 0.15</td>
<td>0.30 ± 0.14<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>0.17 ± 0.04<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 20:4 n-6</td>
<td>12.06 ± 1.28</td>
<td>10.54 ± 1.51<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>8.90 ± 2.09<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>6.47 ± 1.56<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>7.51 ± 1.62<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>8.16 ± 0.98<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
</tr>
<tr>
<td> 20:5 n-3</td>
<td>1.31 ± 0.27</td>
<td>0.20 ± 0.02</td>
<td>0.32 ± 0.12</td>
<td>0.98 ± 0.13</td>
<td>4.58 ± 1.66<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>7.20 ± 1.57<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 22:4 n-6</td>
<td>0.08 ± 0.02</td>
<td>0.11 ± 0.05</td>
<td>0.10 ± 0.01</td>
<td>0.04 ± 0.04</td>
<td>0.04 ± 0.04</td>
<td>0.00 ± 0.00<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 22:5 n-6</td>
<td>0.13 ± 0.04</td>
<td>0.86 ± 0.06<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>0.55 ± 0.07<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.15 ± 0.04<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>0.02 ± 0.03<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>0.00 ± 0.00<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 22:5 n-3</td>
<td>0.30 ± 0.02</td>
<td>0.04 ± 0.05<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.11 ± 0.03<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.15 ± 0.02<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.54 ± 0.14<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>0.70 ± 0.06<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 22:6 n-3</td>
<td>7.11 ± 1.14</td>
<td>6.62 ± 0.52</td>
<td>6.29 ± 1.00</td>
<td>9.50 ± 3.01</td>
<td>16.65 ± 3.13<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>22.13 ± 3.37<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td colspan="7">Liver</td>
</tr>
<tr>
<td> 16:0</td>
<td>19.49 ± 0.59</td>
<td>22.01 ± 0.36<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>23.74 ± 0.41<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>24.96 ± 0.43<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>26.03 ± 0.86<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>25.12 ± 1.21<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
</tr>
<tr>
<td> 16:1 n-7</td>
<td>2.82 ± 0.84</td>
<td>6.67 ± 0.91<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>6.34 ± 0.50<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>7.33 ± 0.69<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>6.51 ± 0.64<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>5.08 ± 0.67<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
</tr>
<tr>
<td> 18:0</td>
<td>10.81 ± 2.16</td>
<td>3.15 ± 0.12<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>4.04 ± 0.53<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>4.46 ± 0.79<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>6.85 ± 1.32<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>9.86 ± 1.22<sup><xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 18:1 n-9</td>
<td>23.63 ± 6.91</td>
<td>49.67 ± 1.76<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>46.12 ± 1.37<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>42.62 ± 2.91<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>28.85 ± 9.65<sup><xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>17.81 ± 3.29<sup><xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 18:1 n-7</td>
<td>4.72 ± 0.91</td>
<td>9.56 ± 0.85<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>9.31 ± 0.65<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>8.37 ± 0.65<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>3.33 ± 1.74<sup><xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>1.49 ± 0.25<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 18:2 n-6</td>
<td>13.44 ± 1.21</td>
<td>1.45 ± 0.26<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>1.91 ± 0.70<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>2.28 ± 0.58<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>2.47 ± 0.77<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>2.23 ± 0.50<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
</tr>
<tr>
<td> 18:3 n-6</td>
<td>0.14 ± 0.02</td>
<td>0.06 ± 0.02<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.05 ± 0.02<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.03 ± 0.01<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.02 ± 0.01<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.02 ± 0.00<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 18:3 n-3</td>
<td>0.35 ± 0.09</td>
<td>0.03 ± 0.01<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.03 ± 0.02<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.05 ± 0.02<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.12 ± 0.06<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>0.10 ± 0.02<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
</tr>
<tr>
<td> 20:3 n-9</td>
<td>0.39 ± 0.05</td>
<td>1.44 ± 0.13<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>1.25 ± 0.28<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.63 ± 0.13<sup><xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>0.08 ± 0.07<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>0.02 ± 0.01<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 20:3 n-6</td>
<td>1.42 ± 0.20</td>
<td>0.24 ± 0.02<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.32 ± 0.09<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.30 ± 0.07<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.15 ± 0.05<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.14 ± 0.03<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
</tr>
<tr>
<td> 20:4 n-6</td>
<td>10.25 ± 3.20</td>
<td>1.43 ± 0.15<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>1.95 ± 0.45<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>2.02 ± 0.61<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>3.36 ± 0.48<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>4.99 ± 0.74<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 20:5 n-3</td>
<td>0.63 ± 0.02</td>
<td>0.04 ± 0.00</td>
<td>0.05 ± 0.02</td>
<td>0.20 ± 0.07</td>
<td>1.99 ± 1.08<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>3.72 ± 0.28<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 22:4 n-6</td>
<td>0.18 ± 0.06</td>
<td>0.04 ± 0.01<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.05 ± 0.01<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.04 ± 0.02<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.08 ± 0.02<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.07 ± 0.01<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
</tr>
<tr>
<td> 22:5 n-6</td>
<td>0.15 ± 0.06</td>
<td>0.18 ± 0.03</td>
<td>0.14 ± 0.02</td>
<td>0.06 ± 0.01<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>0.01 ± 0.02<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>0.00 ± 0.00<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 22:5 n-3</td>
<td>0.41 ± 0.02</td>
<td>0.02 ± 0.01<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.04 ± 0.03<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>0.10 ± 0.03</td>
<td>0.87 ± 0.40<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>1.05 ± 0.24<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td> 22:6 n-3</td>
<td>9.01 ± 1.65</td>
<td>1.41 ± 0.16<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>1.75 ± 0.30<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref></sup></td>
<td>3.82 ± 0.96</td>
<td>16.94 ± 8.47<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
<td>26.60 ± 4.41<sup><xref ref-type="table-fn" rid="table-fn5-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn6-0148607111414580">c</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0148607111414580">
<p>HCD, high-carbohydrate diet.</p>
</fn>
<fn id="table-fn4-0148607111414580">
<label>a</label>
<p>The group means were compared with analysis of variance for difference with post hoc analysis based on Tukey test.</p>
</fn>
<fn id="table-fn5-0148607111414580">
<label>b</label>
<p><italic>P</italic> &lt; .05, compared to control.</p>
</fn>
<fn id="table-fn6-0148607111414580">
<label>c</label>
<p><italic>P</italic> &lt; .05, compared to essential fatty acid–deficient HCD-0 group.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-0148607111414580" position="float">
<label>Table 3.</label>
<caption>
<p>Fatty Acid Composition of Serum and Liver in the 9-Week Experiment<sup><xref ref-type="table-fn" rid="table-fn8-0148607111414580">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table3-0148607111414580" xlink:href="10.1177_0148607111414580-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="3">Serum</th>
<th align="center" colspan="3">Liver</th>
</tr>
<tr>
<th align="left">Mole, %</th>
<th align="center">Control</th>
<th align="center">HCD-0L</th>
<th align="center">HCD-2.1L</th>
<th align="center">Control</th>
<th align="center">HCD-0L</th>
<th align="center">HCD-2.1L</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:0</td>
<td>21.99 ± 1.26</td>
<td>20.38 ± 0.52</td>
<td>26.11 ± 1.56<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
<td>22.88 ± 1.21</td>
<td>21.40 ± 0.46</td>
<td>23.15 ± 1.01<sup><xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td>16:1 n-7</td>
<td>4.97 ± 1.07</td>
<td>10.82 ± 1.05<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
<td>7.16 ± 1.68<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
<td>6.76 ± 0.68</td>
<td>11.34 ± 0.62<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>12.43 ± 0.93<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
</tr>
<tr>
<td>18:0</td>
<td>11.10 ± 0.56</td>
<td>10.37 ± 0.59</td>
<td>12.84 ± 1.70<sup><xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
<td>8.30 ± 0.40</td>
<td>3.08 ± 0.32<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>6.85 ± 0.55<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td>18:1 n-9</td>
<td>15.97 ± 1.12</td>
<td>25.10 ± 1.42<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>14.67 ± 1.86<sup><xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
<td>26.45 ± 4.13</td>
<td>43.88 ± 0.96<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>28.03 ± 2.24<sup><xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td>18:1 n-7</td>
<td>4.08 ± 0.62</td>
<td>6.97 ± 0.46<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>2.40 ± 0.53<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
<td>5.58 ± 0.51</td>
<td>9.58 ± 0.86<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>4.33 ± 0.22<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td>18:2 n-6</td>
<td>16.08 ± 0.82</td>
<td>2.67 ± 0.66<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>2.27 ± 0.56<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>10.91 ± 1.43</td>
<td>0.54 ± 0.13<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>1.54 ± 0.36<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
</tr>
<tr>
<td>18:3 n-6</td>
<td>0.16 ± 0.09</td>
<td>0.00 ± 0.00<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>0.00 ± 0.00<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>0.03 ± 0.03</td>
<td>0.00 ± 0.00<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>0.00 ± 0.00<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
</tr>
<tr>
<td>18:3 n-3</td>
<td>0.25 ± 0.07</td>
<td>0.00 ± 0.00<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>0.00 ± 0.00<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>0.25 ± 0.04</td>
<td>0.00 ± 0.00<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>0.05 ± 0.01<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td>20:3 n-9</td>
<td>0.92 ± 0.19</td>
<td>13.02 ± 0.73<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>0.47 ± 0.38<sup><xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
<td>0.59 ± 0.13</td>
<td>2.20 ± 0.34<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>0.13 ± 0.06<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td>20:3 n-6</td>
<td>2.11 ± 0.11</td>
<td>0.73 ± 0.13<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>0.26 ± 0.04<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
<td>1.42 ± 0.24</td>
<td>0.13 ± 0.03<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>0.14 ± 0.03<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
</tr>
<tr>
<td>20:4 n-6</td>
<td>14.55 ± 1.69</td>
<td>4.29 ± 0.46<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>8.74 ± 1.12<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
<td>9.33 ± 1.12</td>
<td>1.11 ± 0.21<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>2.83 ± 0.51<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td>20:5 n-3</td>
<td>0.39 ± 0.07</td>
<td>0.00 ± 0.00</td>
<td>7.90 ± 0.99<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
<td>0.18 ± 0.06</td>
<td>0.00 ± 0.00</td>
<td>2.87 ± 0.43<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td>22:4 n-6</td>
<td>0.12 ± 0.02</td>
<td>0.03 ± 0.02<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>0.01 ± 0.01<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>0.21 ± 0.04</td>
<td>0.00 ± 0.00<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>0.04 ± 0.01<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td>22:5 n-6</td>
<td>0.51 ± 0.10</td>
<td>0.50 ± 0.29</td>
<td>0.00 ± 0.00<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
<td>0.42 ± 0.12</td>
<td>0.13 ± 0.03<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>0.00 ± 0.00<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td>22:5 n-3</td>
<td>0.13 ± 0.03</td>
<td>0.11 ± 0.25</td>
<td>0.34 ± 0.02</td>
<td>0.12 ± 0.03</td>
<td>0.00 ± 0.00</td>
<td>0.97 ± 0.12<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
</tr>
<tr>
<td>22:6 n-3</td>
<td>4.63 ± 0.29</td>
<td>2.00 ± 0.28<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>14.77 ± 0.93<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
<td>3.75 ± 0.51</td>
<td>0.51 ± 0.11<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref></sup></td>
<td>13.59 ± 1.98<sup><xref ref-type="table-fn" rid="table-fn9-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn10-0148607111414580">c</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0148607111414580">
<p>HCD, high-carbohydrate diet.</p>
</fn>
<fn id="table-fn8-0148607111414580">
<label>a</label>
<p>The group means were compared with analysis of variance for difference with post hoc analysis based on Tukey test.</p>
</fn>
<fn id="table-fn9-0148607111414580">
<label>b</label>
<p><italic>P</italic> &lt; .05, compared to control.</p>
</fn>
<fn id="table-fn10-0148607111414580">
<label>c</label>
<p><italic>P</italic> &lt; .05, compared to essential fatty acid–deficient HCD-0 group.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section15-0148607111414580">
<title>EPA</title>
<p>EPA (20:5 n-3) is an important downstream product of ALA. EPA is not present in the control soybean-based diet and is synthesized in vivo from ALA. Its mean percentage in the serum and liver at 19 days was 1.31% and 0.63%, respectively (<xref ref-type="table" rid="table2-0148607111414580">Table 2</xref>). After 9 weeks, the mean percentage decreased to 0.39% and 0.18% in the serum and liver, respectively (<xref ref-type="table" rid="table3-0148607111414580">Table 3</xref>). Mice in the HCD-only and HCD-0 groups, both with expected EFAD, had lower percentages of EPA in the serum and liver compared to the control mice. When mice in the 19-day experiment were provided increasing amounts of DHA, the percentage of serum and liver EPA increased steadily compared to the control group. After 9 weeks, mice in the HCD-0 group had an essentially undetectable level of EPA in both the serum and liver, whereas the percentage of EPA in the HCD-2.1 mice was increased.</p>
</sec>
<sec id="section16-0148607111414580">
<title>DHA</title>
<p>Like EPA, DHA (22:6 n-3) is an important downstream product of ALA and is not present in the control diet. By increasing the dietary amounts of pure DHA, the mean percentage of DHA in serum increased from 6.29% in HCD-0 group to 9.50%, 16.65%, and 22.13% in the HCD-0.21, HCD-2.1 and HCD-4.2 groups, respectively (<xref ref-type="table" rid="table2-0148607111414580">Table 2</xref>). The percentage of liver DHA also increased from 1.75% in the HCD-0 group to 3.82%, 16.94%, and 26.60% in the HCD-0.21, HCD-2.1, and HCD-4.2 groups, respectively. The 9-week experiment also showed a significant increase in the percentage of serum and liver DHA in the HCD-2.1 mice compared to HCD-0 mice.</p>
</sec>
<sec id="section17-0148607111414580">
<title>AA</title>
<p>The mean percentage of AA (20:4 n-6) was 12.06% in the serum and 10.25% in control mouse livers after 19 days (<xref ref-type="table" rid="table2-0148607111414580">Table 2</xref>). These values remained relatively unchanged after 9 weeks (<xref ref-type="table" rid="table3-0148607111414580">Table 3</xref>). The mean percentage of AA remained relatively constant in the serum of mice in the HCD-only and HCD-0 groups, whereas the mean percentage in the liver decreased. After 9 weeks, the mean percentage of serum AA in the HCD-0 group decreased to 4.29% while the liver levels continued to be low at 1.11%. Mice in the HCD-2.1 and HCD-4.2 groups had an intermediate mean percentage of serum AA at 7.51% and 8.16%, respectively. In addition, the mean percentage of serum and liver AA remained relatively unchanged at 8.74% after 9 weeks in the HCD-2.1 group. The percentage of liver AA also remained stable (3.36% after 19 days and 2.83% after 9 weeks).</p>
</sec>
</sec>
<sec id="section18-0148607111414580">
<title>Evidence of EFAD</title>
<sec id="section19-0148607111414580">
<title>T:T ratio</title>
<p>As expected, control mice in the 19-day and 9-week experiments did not have EFAD, as their serum and liver T:T ratios were well below 0.2 (<xref ref-type="table" rid="table4-0148607111414580">Tables 4</xref> and <xref ref-type="table" rid="table5-0148607111414580">5</xref>). Fat-free mice (HCD-only) and EFA-free mice (HCD-0) all had severe EFAD with elevated serum and liver T:T ratios after 19 days (<xref ref-type="table" rid="table4-0148607111414580">Table 4</xref>). The T:T ratio of HCD-0 mice became even more elevated after 9 weeks (<xref ref-type="table" rid="table5-0148607111414580">Table 5</xref>), suggesting more severe EFAD. HCD-0.21 mice had mean serum and liver T:T ratios, surpassing the value of 0.2 indicating EFAD. HCD-2.1 mice had serum and liver T:T ratios well below the value 0.2 after 19 days and remained similar to the control group after 9 weeks. HCD-4.2 mouse serum and liver T:T ratios were well below 0.2.</p>
<table-wrap id="table4-0148607111414580" position="float">
<label>Table 4.</label>
<caption>
<p>Triene:Tetraene Ratio and Essential Fatty Acid Index of Serum and Liver in the 19-Day Experiment<sup><xref ref-type="table-fn" rid="table-fn12-0148607111414580">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table4-0148607111414580" xlink:href="10.1177_0148607111414580-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">Triene:Tetraene Ratio</th>
<th align="center" colspan="2">Essential Fatty Acid Index</th>
</tr>
<tr>
<th align="left">Group</th>
<th align="center">Serum</th>
<th align="center">Liver</th>
<th align="center">Serum</th>
<th align="center">Liver</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.03 ± 0.02</td>
<td>0.04 ± 0.01</td>
<td>2.20 ± 0.46</td>
<td>1.25 ± 0.58</td>
</tr>
<tr>
<td>HCD-only</td>
<td>0.84 ± 0.27<sup><xref ref-type="table-fn" rid="table-fn13-0148607111414580">b</xref></sup></td>
<td>1.02 ± 0.14<sup><xref ref-type="table-fn" rid="table-fn13-0148607111414580">b</xref></sup></td>
<td>0.58 ± 0.10<sup><xref ref-type="table-fn" rid="table-fn13-0148607111414580">b</xref></sup></td>
<td>0.07 ± 0.01<sup><xref ref-type="table-fn" rid="table-fn13-0148607111414580">b</xref></sup></td>
</tr>
<tr>
<td>HCD-0</td>
<td>0.84 ± 0.35<sup><xref ref-type="table-fn" rid="table-fn13-0148607111414580">b</xref></sup></td>
<td>0.66 ± 0.18<sup><xref ref-type="table-fn" rid="table-fn13-0148607111414580">b</xref></sup></td>
<td>0.56 ± 0.21<sup><xref ref-type="table-fn" rid="table-fn13-0148607111414580">b</xref></sup></td>
<td>0.10 ± 0.02<sup><xref ref-type="table-fn" rid="table-fn13-0148607111414580">b</xref></sup></td>
</tr>
<tr>
<td>HCD-0.21</td>
<td>0.42 ± 0.10<sup><xref ref-type="table-fn" rid="table-fn13-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn14-0148607111414580">c</xref></sup></td>
<td>0.34 ± 0.13<sup><xref ref-type="table-fn" rid="table-fn13-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn14-0148607111414580">c</xref></sup></td>
<td>0.72 ± 0.15<sup><xref ref-type="table-fn" rid="table-fn13-0148607111414580">b</xref></sup></td>
<td>0.15 ± 0.04<sup><xref ref-type="table-fn" rid="table-fn13-0148607111414580">b</xref></sup></td>
</tr>
<tr>
<td>HCD-2.1</td>
<td>0.02 ± 0.03<sup><xref ref-type="table-fn" rid="table-fn14-0148607111414580">c</xref></sup></td>
<td>0.03 ± 0.02<sup><xref ref-type="table-fn" rid="table-fn13-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn14-0148607111414580">c</xref></sup></td>
<td>1.12 ± 0.46<sup><xref ref-type="table-fn" rid="table-fn13-0148607111414580">b</xref></sup></td>
<td>0.79 ± 0.53</td>
</tr>
<tr>
<td>HCD-4.2</td>
<td>0.00 ± 0.00<sup><xref ref-type="table-fn" rid="table-fn14-0148607111414580">c</xref></sup></td>
<td>0.00 ± 0.00<sup><xref ref-type="table-fn" rid="table-fn13-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn14-0148607111414580">c</xref></sup></td>
<td>1.87 ± 0.52<sup><xref ref-type="table-fn" rid="table-fn14-0148607111414580">c</xref></sup></td>
<td>1.63 ± 0.44<sup><xref ref-type="table-fn" rid="table-fn14-0148607111414580">c</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn11-0148607111414580">
<p>HCD, high-carbohydrate diet.</p>
</fn>
<fn id="table-fn12-0148607111414580">
<label>a</label>
<p>The group means were compared with analysis of variance for difference with post hoc analysis based on Tukey test.</p>
</fn>
<fn id="table-fn13-0148607111414580">
<label>b</label>
<p><italic>P</italic> &lt; .05, compared to control.</p>
</fn>
<fn id="table-fn14-0148607111414580">
<label>c</label>
<p><italic>P</italic> &lt; .05, compared to essential fatty acid–deficient HCD-0 group.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table5-0148607111414580" position="float">
<label>Table 5.</label>
<caption>
<p>Triene:Tetraene Ratio and Essential Fatty Acid Index of Serum and Liver in the 9-Week Experiment<sup><xref ref-type="table-fn" rid="table-fn16-0148607111414580">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table5-0148607111414580" xlink:href="10.1177_0148607111414580-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">Triene:Tetraene Ratio</th>
<th align="center" colspan="2">Essential Fatty Acid Index</th>
</tr>
<tr>
<th align="left">Group</th>
<th align="center">Serum</th>
<th align="center">Liver</th>
<th align="center">Serum</th>
<th align="center">Liver</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.06 ± 0.02</td>
<td>0.06 ± 0.01</td>
<td>1.49 ± 0.23</td>
<td>0.67 ± 0.14</td>
</tr>
<tr>
<td>HCD-0L</td>
<td>3.07 ± 0.44<sup><xref ref-type="table-fn" rid="table-fn17-0148607111414580">b</xref></sup></td>
<td>2.02 ± 0.29<sup><xref ref-type="table-fn" rid="table-fn17-0148607111414580">b</xref></sup></td>
<td>0.19 ± 0.04<sup><xref ref-type="table-fn" rid="table-fn17-0148607111414580">b</xref></sup></td>
<td>0.01 ± 0.00<sup><xref ref-type="table-fn" rid="table-fn17-0148607111414580">b</xref></sup></td>
</tr>
<tr>
<td>HCD-2.1L</td>
<td>0.05 ± 0.03<sup><xref ref-type="table-fn" rid="table-fn18-0148607111414580">c</xref></sup></td>
<td>0.05 ± 0.02<sup><xref ref-type="table-fn" rid="table-fn18-0148607111414580">c</xref></sup></td>
<td>1.40 ± 0.22<sup><xref ref-type="table-fn" rid="table-fn18-0148607111414580">c</xref></sup></td>
<td>0.48 ± 0.08<sup><xref ref-type="table-fn" rid="table-fn17-0148607111414580">b</xref>,<xref ref-type="table-fn" rid="table-fn18-0148607111414580">c</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn15-0148607111414580">
<p>HCD, high-carbohydrate diet.</p>
</fn>
<fn id="table-fn16-0148607111414580">
<label>a</label>
<p>The group means were compared with analysis of variance for difference with post hoc analysis based on Tukey test.</p>
</fn>
<fn id="table-fn17-0148607111414580">
<label>b</label>
<p><italic>P</italic> &lt; .05, compared to control.</p>
</fn>
<fn id="table-fn18-0148607111414580">
<label>c</label>
<p><italic>P</italic> &lt; .05, compared to essential fatty acid–deficient HCD-0L group.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section20-0148607111414580">
<title>EFA index</title>
<p>The EFA index, another biochemical marker of EFAD, was also used to evaluate these mice for evidence of biochemical EFAD. The results showed that both the fat-free and the EFA-deficient mice had suppressed serum and liver EFA indices compared to control mice (<xref ref-type="table" rid="table4-0148607111414580">Table 4</xref>) in the 19-day experiment. Mice that received 2.1% of their calories from DHA and AA (HCD-2.1) had significantly lower serum EFA index after 19 days. However, their serum EFA indices after 9 weeks were equivalent to those of control mice.</p>
</sec>
<sec id="section21-0148607111414580">
<title>Mead acid</title>
<p>ALA &gt; LA &gt; oleic acid is the order of affinity for the elongation and desaturation enzymes. In the state of EFAD, Mead acid (20:3 n-9) is synthesized from oleic acid (18:1 n-9), which serves to partially compensate for the reduction in double bonds in tissue membranes due to the lack of precursor ω-3 and ω-6 fatty acids. Therefore, an increased Mead acid level is another important indicator of EFAD. In the 19-day experiment, the mean percentage of Mead acid was 0.41% in the serum and 0.39% in the liver of the control mice (<xref ref-type="table" rid="table2-0148607111414580">Table 2</xref>). As expected, mean percentages of Mead acid increased significantly in the serum and livers of mice in the HCD-only and HCD-0 groups compared to the control group. Mice in the HCD-0.21 group also had a significant but smaller increase in the percentage of serum Mead acid compared to control mice. Mice in the HCD-2.1 and HCD-4.2 groups had even lower percentages of Mead acid in their livers compared to controls. Similarly, results from the 9-week experiment showed a significant increase in serum and liver Mead acid percentages in the HCD-0 group (<xref ref-type="table" rid="table3-0148607111414580">Table 3</xref>). There was no significant difference in serum and liver Mead acid percentage in the HCD-2.1 group compared to the control group.</p>
</sec>
</sec>
<sec id="section22-0148607111414580">
<title>Histologic Evaluation and Degree of Steatosis</title>
<p>In both experiments, there were no inflammatory cells present on liver sections, suggesting that there was no evidence of steatohepatitis in any group (<xref ref-type="fig" rid="fig2-0148607111414580">Figures 2</xref> and<xref ref-type="fig" rid="fig3-0148607111414580">3</xref>). Control mice showed normal hepatic architecture with no hepatic steatosis. In contrast, liver sections from the HCD-only and the HCD-0 mice exhibited diffuse macro- and microvesicular steatosis in the periportal and midzone areas. Liver sections from mice in the HCD-0.21 group showed moderately preserved hepatic architecture, less macrovesicular steatosis, and more sparing of the midzone. In the 19-day and 9-week experiments, livers of mice receiving 2% DHA and 0.1% AA (HCD-2.1 and HCD-2.1L) had well-preserved hepatic architecture with rare focal microvacuoles in the cytoplasm of the midzone hepatocytes. No macro- or microvesicular steatosis was observed in liver sections of HCD-4.2 mice in the 19-day experiment.</p>
<fig id="fig2-0148607111414580" position="float">
<label>Figure 2.</label>
<caption>
<p>Liver histology and degree of hepatic steatosis after 19 days. Hematoxylin and eosin–stained liver sections of mice with different lipid supplementation. Liver sections from control mice showed normal hepatic architecture (A). HCD-only livers exhibited diffuse macro- and microvesicular steatosis in the periportal and midzone hepatocytes (B). HCD-0 livers were similar to HCD-only livers (C). HCD-0.21 livers showed a moderate reduction of steatosis in the periportal and midzone regions (D). HCD-2.1 and HCD-4.2 livers had well-preserved hepatic architecture with no focal microvacuoles (E-F). The results were reflected in the steatosis scores of these groups (G) in which mice in the HCD-only, HCD-0, and HCD-0.21 groups had higher median scores than control animals. Data are expressed as median ± interquartile range. Group medians were compared with the Kruskal-Wallis test.</p>
<p>HCD, high-carbohydrate diet.</p>
<p>*<italic>P</italic> &lt; .05.</p>
</caption>
<graphic xlink:href="10.1177_0148607111414580-fig2.tif"/></fig>
<fig id="fig3-0148607111414580" position="float">
<label>Figure 3.</label>
<caption>
<p>Liver histology and degree of steatosis after 9 weeks. Livers of the control mice (A); the HCD-0L mice (B), with severe macrovesicular steatosis; and the HCD-2.1L mice (C), which retained normal architecture. Livers of the HCD-0L mice had a significantly higher steatosis score compared to the control and HCD-2.1L mice. Data are expressed as median ± interquartile range. Group medians were compared with the Kruskal-Wallis test.</p>
<p>HCD, high-carbohydrate diet.</p>
<p>*<italic>P</italic> &lt; .05.</p>
</caption>
<graphic xlink:href="10.1177_0148607111414580-fig3.tif"/></fig>
</sec>
<sec id="section23-0148607111414580">
<title>Serum Liver Enzymes</title>
<p>ALT levels were obtained to assess the degree of liver injury. Values from the control mice that were maintained on the standard rodent diet were used as a reference. In the 19-day experiment, the ALT value in the HCD-only group was higher but not statistically significant compared to the control group (<xref ref-type="fig" rid="fig4-0148607111414580">Figure 4A</xref>). However, the ALT level of the HCD-4.2 group was significantly lower than the HCD-only group. In the 9-week experiment, HCD-0 mice had a higher ALT value than the control and HCD-2.1 mice (<xref ref-type="fig" rid="fig4-0148607111414580">Figure 4B</xref>).</p>
<fig id="fig4-0148607111414580" position="float">
<label>Figure 4.</label>
<caption>
<p>Serum ALT in the 19-day and 9-week experiments. After 19 days (A), the mean ALT value in control mice was 36.3 ± 13.9 IU/L. HCD-only, HCD-0, and HCD-0.21 values were higher than the control value but not significant (77.8 ± 16.0 IU/L, 54.4 ± 3.8 IU/L, and 69.0 ± 23.1 IU/L, respectively). The ALT value of the HCD-2.1 mice was 35.8 ± 6.9 IU/L. The ALT value of the HCD-4.2 mice (28.3 ± 1.1 IU/L) was significantly lower than ALT values of HCD-only and HCD-0 mice. After 9 weeks (B), the mean ALT value of the HCD-0 mice was 57.0 ± 4.6 IU/L, which was significantly higher than the ALT values of the control mice (29.4 ± 3.6 IU/L) and the HCD-2.1 mice (31.0 ± 4.2 IU/L). Data are expressed as mean ± SD. The group means were compared with analysis of variance for difference, with post hoc analysis based on the Tukey test.</p>
<p>ALT, alanine aminotransferase; HCD, high-carbohydrate diet.</p>
<p>*<italic>P</italic> &lt; .05.</p>
</caption>
<graphic xlink:href="10.1177_0148607111414580-fig4.tif"/></fig>
</sec>
</sec>
<sec id="section24-0148607111414580" sec-type="discussion">
<title>Discussion</title>
<p>ALA and LA are considered to be the only EFAs. EFAs are termed as such because they are required for important body functions but cannot be synthesized in the body.<sup><xref ref-type="bibr" rid="bibr18-0148607111414580">18</xref></sup> Clinical signs of EFAD typically include growth retardation and dermatitis.<sup><xref ref-type="bibr" rid="bibr19-0148607111414580">19</xref></sup> However, these clinical signs are now rarely seen in adults with the wide availability of PN and lipid emulsions containing EFA; therefore, biochemical markers such as T:T ratio and EFA index were derived to identify the development of biochemical EFAD.<sup><xref ref-type="bibr" rid="bibr15-0148607111414580">15</xref></sup> In animals, clinical evidence of EFAD is often not reported<sup><xref ref-type="bibr" rid="bibr13-0148607111414580">13</xref></sup> and generally requires a long duration of feeding an EFAD diet and/or feeding beginning early in infancy. In our experiments, adult mice fed fat-deficient and EFA-deficient diets exhibited biochemical EFAD with accompanying hepatic steatosis without any clinical signs of EFAD.</p>
<p>Our results demonstrate that mice provided with at least 2% of their calories from DHA and at least 0.1% of calories from AA did not develop clinical or biochemical evidence of EFAD. The prevention of biochemical evidence of EFAD was demonstrated using a combination of T:T ratio, EFA index, and Mead acid level as well as the prevention of hepatic steatosis. In fact, the mean Mead acid levels were lower in the HCD-2.1 and HCD-4.2 groups as compared to the control group. This presumably reflects the impact of DHA and/or EPA to reduce elongation and desaturation of oleic acid. In the animals that received DHA and AA yet did not develop evidence of EFAD, the percentage of the traditional EFA, ALA, and LA remained significantly lower than in control animals. This presumably reflects their absence in the diets containing DHA and AA and the lack of appreciable retroconversion of DHA beyond the level of EPA (ie, to ALA) or of AA to LA. Furthermore, ALA and LA, which are present in the control diet but not in the other diets, would competitively inhibit the elongation of oleic acid to Mead acid and thus lead to lower levels of Mead acid. However, the level of Mead acid and the T:T ratio were maintained in the higher DHA- and AA-containing diets as in the control diets, reflecting equivalent EFA status, whereas the AA level was lower. This is thought to reflect the ability of EPA to substitute for AA in tissue membranes.<sup><xref ref-type="bibr" rid="bibr20-0148607111414580">20</xref></sup> Since a lower AA level in membranes produced by EPA supplementation is associated with an anti-inflammatory effect,<sup><xref ref-type="bibr" rid="bibr21-0148607111414580">21</xref></sup> this suggests a potential benefit for the use of DHA and AA to meet EFA requirements. While ALA and LA can meet all the needs for EPA, DHA, and AA, it appears that DHA and AA can alternatively serve as the EFAs.</p>
<p>The lipid mixture used in our experiments had a 20:1 ratio of DHA:AA. This ratio was used to mimic the ratio of n-3 to n-6 fatty acids present in the oil of cold water fish. HCO was added to increase the non-EFA fat content. Since coconut oil contains approximately 0.1% ALA and 1.9% LA, it was hydrogenated to ensure that only trace LA was present. Although there have been reports of retarded growth in infants and growing animals on high ω-3:ω-6 ratio diets,<sup><xref ref-type="bibr" rid="bibr22-0148607111414580">22</xref>,<xref ref-type="bibr" rid="bibr23-0148607111414580">23</xref></sup> the effect is most likely due to lack of AA<sup><xref ref-type="bibr" rid="bibr24-0148607111414580">24</xref></sup> since EPA can so profoundly lower AA levels. In addition, in a previous 9-week study, we showed that a diet containing 13% of calories from fish oil that contained EPA, DHA, and AA prevented EFAD and maintained growth despite inadequate amounts of LA in the fish oil.<sup><xref ref-type="bibr" rid="bibr7-0148607111414580">7</xref></sup> In this study, we showed that a 20:1 ratio of DHA:AA results in an increase in serum and liver DHA levels while keeping AA at levels significantly lower than with the control diet despite similar EFA status. The data also show that when mice receive increasing amounts of exogenous DHA, both serum and liver EPA increase. Since these mice received no exogenous EPA, this is likely to be the result of retroconversion of DHA to EPA, as previously described.<sup><xref ref-type="bibr" rid="bibr25-0148607111414580">25</xref></sup> When mice received DHA:AA at 4.2% of their daily calories, they developed weight loss in the first week but eventually caught up with the control group by day 14. This effect was confirmed on repeated experiments. In the HCD-4.2 group, each mouse received approximately 200 mg/kg/d of AA, which is lethal if administered alone in intravenous form.<sup><xref ref-type="bibr" rid="bibr16-0148607111414580">16</xref>,<xref ref-type="bibr" rid="bibr17-0148607111414580">17</xref></sup> However, when given with DHA in oral form, the level of toxicity is often diminished.<sup><xref ref-type="bibr" rid="bibr26-0148607111414580">26</xref></sup> The results suggest that the amount of AA administered to the HCD-4.2 group was relatively toxic, which resulted in weight loss likely due to an increased inflammatory response as a result of increased inflammatory cytokine production. Continued exposure to high-dose AA might have enabled these mice to adapt and metabolize AA more efficiently to avoid a toxic effect. Due to the toxic effect of AA, this group was not included in the 9-week study.</p>
<p>We also demonstrated that DHA and AA, with the background intake of other fat as HCO, are able to prevent hepatic steatosis in our model. Although enhanced de novo lipogenesis and resultant hepatic steatosis occur secondary to EFAD, we have shown that the route of administration and EFAD may act independently when fat is provided parenterally.<sup><xref ref-type="bibr" rid="bibr27-0148607111414580">27</xref></sup> However, in this study, all feeding occurred by the enteral route. It is also known that fat intake of any type can impair de novo lipogenesis, albeit to different degrees.<sup><xref ref-type="bibr" rid="bibr28-0148607111414580">28</xref></sup> Nonetheless, this study showed that the degree of steatosis was similar in the fat-free diet and with added HCO only, suggesting that EFAD was the principal factor. One explanation for the prevention of hepatic steatosis is the lack of or major reduction in de novo lipogenesis in mice receiving DHA/AA. One of the markers of de novo lipogenesis is the “desaturation index,” which is the serum ratio of 18:1/18:0.<sup><xref ref-type="bibr" rid="bibr29-0148607111414580">29</xref></sup> Results from this study showed that desaturation indices were higher in the fat-free and HCO-only groups (2.33 and 2.56, respectively) compared to the control value of 1.34. This ratio decreased to 2.34, 2.03, and 1.41 in the HCD-0.21, HCD-2.1, and HCD-4.2 groups, respectively. This reflects decreased de novo lipogenesis with increasing DHA. These results are consistent with the histologic findings.</p>
<p>Although this is beyond the scope of this study, one limitation is that the lipid mixtures employed do not reflect the normal dietary intake of PUFA nor provide the usual PUFA tissue levels in either humans or rodents. The basal diet used was based on our previous experimentation where mice fed with this diet developed EFAD and hepatic steatosis,<sup><xref ref-type="bibr" rid="bibr8-0148607111414580">8</xref></sup> the latter of which we viewed as an excellent metabolic measure of EFAD. The lipid mixtures were created to ensure that DHA and AA were the sole sources of PUFA. However, by eliminating other sources of PUFA, we can confidently conclude that the DHA and AA are the only two responsible dietary PUFAs in this study, although their effect on other PUFAs such as EPA in vivo would have a major impact on metabolism. These results can therefore serve as the basis for a future study of other diets using this expanded definition of EFAs particularly where EPA is included in the dietary mix.</p>
<p>These results should be interpreted with caution as they were derived from murine models. Moreover, the optimal amount of DHA and AA to prevent EFAD and hepatic steatosis is yet to be determined. Further studies need to be performed to determine the optimal ratio of DHA:AA, as well as the minimal requirement of each fatty acid to design novel parenteral lipid emulsions that provide adequate amounts of EFA to prevent and treat EFAD while limiting hepatic steatosis and reducing AA due to its putative anti-inflammatory effects.</p>
<p>Overall, this is the first demonstration that the provision of DHA and AA can prevent biochemical and clinical evidence of EFAD in a short- and long-term murine model. DHA and AA supplementation can also prevent hepatic steatosis as an important metabolic consequence of EFAD. These changes occurred despite dietary absence of ALA and LA and while their serum and tissue levels diminished. This suggests that the paradigm that ALA and LA are the only EFA should at least be reconsidered.</p>
</sec>
</body>
<back>
<ack><p>An abstract describing these findings was presented at the 40th annual meeting of the American Pediatric Surgery Association. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Diabetes and Digestive and Kidney Diseases or the National Institutes of Health.</p></ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: HDL and EMF were recipients of the Joshua Ryan Rappaport Fellowship. EMF was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (F32DK083880). MP was supported by the National Institutes of Health (DK069621-05). HDL, JAM, VEM, EMF, and MP were supported by the Children’s Hospital Surgical Foundation and the Vascular Biology Program (Boston, MA).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0148607111414580">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aaes-Jorgensen</surname><given-names>E</given-names></name>
<name><surname>Leppik</surname><given-names>EE</given-names></name>
<name><surname>Hayes</surname><given-names>HW</given-names></name>
<name><surname>Holman</surname><given-names>RT</given-names></name>
</person-group>. <article-title>Essential fatty acid deficiency: II. In adult rats</article-title>. <source>J Nutr</source>. <year>1958</year>;<volume>66</volume>:<fpage>245</fpage>-<lpage>259</lpage>.</citation>
</ref>
<ref id="bibr2-0148607111414580">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Das</surname><given-names>UN</given-names></name>
</person-group>. <article-title>Essential fatty acids: biochemistry, physiology and pathology</article-title>. <source>Biotechnol J</source>. <year>2006</year>;<volume>1</volume>:<fpage>420</fpage>-<lpage>439</lpage>.</citation>
</ref>
<ref id="bibr3-0148607111414580">
<label>3.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Voet</surname><given-names>DV</given-names></name>
<name><surname>Voet</surname><given-names>JG</given-names></name>
</person-group>. <source>Biochemistry</source>. <edition>3rd ed.</edition> <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Wiley &amp; Sons</publisher-name>; <year>2004</year>.</citation>
</ref>
<ref id="bibr4-0148607111414580">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carlson</surname><given-names>SE</given-names></name>
<name><surname>Werkman</surname><given-names>SH</given-names></name>
<name><surname>Tolley</surname><given-names>EA</given-names></name>
</person-group>. <article-title>Effect of long-chain n-3 fatty acid supplementation on visual acuity and growth of preterm infants with and without bronchopulmonary dysplasia</article-title>. <source>Am J Clin Nutr</source>. <year>1996</year>;<volume>63</volume>:<fpage>687</fpage>-<lpage>697</lpage>.</citation>
</ref>
<ref id="bibr5-0148607111414580">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bannenberg</surname><given-names>G</given-names></name>
<name><surname>Serhan</surname><given-names>CN</given-names></name>
</person-group>. <article-title>Specialized pro-resolving lipid mediators in the inflammatory response: an update</article-title>. <source>Biochim Biophys Acta</source>. <year>2010</year>;<volume>1801</volume>:<fpage>1260</fpage>-<lpage>1273</lpage>.</citation>
</ref>
<ref id="bibr6-0148607111414580">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Puder</surname><given-names>M</given-names></name>
<name><surname>Valim</surname><given-names>C</given-names></name>
<name><surname>Meisel</surname><given-names>JA</given-names></name>
<etal/>
</person-group>. <article-title>Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury</article-title>. <source>Ann Surg</source>. <year>2009</year>;<volume>250</volume>:<fpage>395</fpage>-<lpage>402</lpage>.</citation>
</ref>
<ref id="bibr7-0148607111414580">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Strijbosch</surname><given-names>RA</given-names></name>
<name><surname>Lee</surname><given-names>S</given-names></name>
<name><surname>Arsenault</surname><given-names>DA</given-names></name>
<etal/>
</person-group>. <article-title>Fish oil prevents essential fatty acid deficiency and enhances growth: clinical and biochemical implications</article-title>. <source>Metabolism</source>. <year>2008</year>;<volume>57</volume>:<fpage>698</fpage>-<lpage>707</lpage>.</citation>
</ref>
<ref id="bibr8-0148607111414580">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alwayn</surname><given-names>IP</given-names></name>
<name><surname>Javid</surname><given-names>PJ</given-names></name>
<name><surname>Gura</surname><given-names>KM</given-names></name>
<name><surname>Nose</surname><given-names>V</given-names></name>
<name><surname>Ollero</surname><given-names>M</given-names></name>
<name><surname>Puder</surname><given-names>M</given-names></name>
</person-group>. <article-title>Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency</article-title>. <source>Hepatology</source>. <year>2004</year>;<volume>39</volume>:<fpage>1176</fpage>-<lpage>1177</lpage>.</citation>
</ref>
<ref id="bibr9-0148607111414580">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Meijer</surname><given-names>VE</given-names></name>
<name><surname>Gura</surname><given-names>KM</given-names></name>
<name><surname>Le</surname><given-names>HD</given-names></name>
<name><surname>Meisel</surname><given-names>JA</given-names></name>
<name><surname>Puder</surname><given-names>M</given-names></name>
</person-group>. <article-title>Fish oil-based lipid emulsions prevent and reverse parenteral nutrition-associated liver disease: the Boston experience</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2009</year>;<volume>33</volume>: <fpage>541</fpage>-<lpage>547</lpage>.</citation>
</ref>
<ref id="bibr10-0148607111414580">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brunt</surname><given-names>EM</given-names></name>
<name><surname>Janney</surname><given-names>CG</given-names></name>
<name><surname>Di Bisceglie</surname><given-names>AM</given-names></name>
<name><surname>Neuschwander-Tetri</surname><given-names>BA</given-names></name>
<name><surname>Bacon</surname><given-names>BR</given-names></name>
</person-group>. <article-title>Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions</article-title>. <source>Am J Gastroenterol</source>. <year>1999</year>;<volume>94</volume>:<fpage>2467</fpage>-<lpage>2474</lpage>.</citation>
</ref>
<ref id="bibr11-0148607111414580">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Folch</surname><given-names>J</given-names></name>
<name><surname>Lees</surname><given-names>M</given-names></name>
<name><surname>Sloane Stanley</surname><given-names>GH</given-names></name>
</person-group>. <article-title>A simple method for the isolation and purification of total lipides from animal tissues</article-title>. <source>J Biol Chem</source>. <year>1957</year>;<volume>226</volume>:<fpage>497</fpage>-<lpage>509</lpage>.</citation>
</ref>
<ref id="bibr12-0148607111414580">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morrison</surname><given-names>WR</given-names></name>
<name><surname>Smith</surname><given-names>LM</given-names></name>
</person-group>. <article-title>Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride-methanol</article-title>. <source>Journal of Lipid Research</source>. <year>1964</year>;<volume>5</volume>:<fpage>600</fpage>-<lpage>608</lpage>.</citation>
</ref>
<ref id="bibr13-0148607111414580">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lukovac</surname><given-names>S</given-names></name>
<name><surname>Los</surname><given-names>EL</given-names></name>
<name><surname>Stellaard</surname><given-names>F</given-names></name>
<name><surname>Rings</surname><given-names>EH</given-names></name>
<name><surname>Verkade</surname><given-names>HJ</given-names></name>
</person-group>. <article-title>Effects of essential fatty acid deficiency on enterohepatic circulation of bile salts in mice</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source>. <year>2009</year>;<volume>297</volume>:<fpage>G520</fpage>-<lpage>G531</lpage>.</citation>
</ref>
<ref id="bibr14-0148607111414580">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saether</surname><given-names>T</given-names></name>
<name><surname>Tran</surname><given-names>TN</given-names></name>
<name><surname>Rootwelt</surname><given-names>H</given-names></name>
<name><surname>Grav</surname><given-names>HJ</given-names></name>
<name><surname>Christophersen</surname><given-names>BO</given-names></name>
<name><surname>Haugen</surname><given-names>TB</given-names></name>
</person-group>. <article-title>Essential fatty acid deficiency induces fatty acid desaturase expression in rat epididymis, but not in testis</article-title>. <source>Reproduction</source>. <year>2007</year>;<volume>133</volume>:<fpage>467</fpage>-<lpage>477</lpage>.</citation>
</ref>
<ref id="bibr15-0148607111414580">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aldamiz-Echevarria</surname><given-names>L</given-names></name>
<name><surname>Vallo</surname><given-names>A</given-names></name>
<name><surname>Aguirre</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Essential fatty acid deficiency profile in patients with nephrotic-range proteinuria</article-title>. <source>Pediatr Nephrol</source>. <year>2007</year>;<volume>22</volume>:<fpage>533</fpage>-<lpage>540</lpage>.</citation>
</ref>
<ref id="bibr16-0148607111414580">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsurumi</surname><given-names>K</given-names></name>
<name><surname>Fujimura</surname><given-names>H</given-names></name>
</person-group>. <article-title>Effect of anti-inflammatory drugs on endotoxin-induced diarrhea in mice</article-title>. <source>Jpn J Pharmacol</source>. <year>1983</year>;<volume>33</volume>:<fpage>165</fpage>-<lpage>173</lpage>.</citation>
</ref>
<ref id="bibr17-0148607111414580">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Myers</surname><given-names>A</given-names></name>
<name><surname>Papadopoulos</surname><given-names>A</given-names></name>
<name><surname>O’Day</surname><given-names>D</given-names></name>
<name><surname>Ramey</surname><given-names>E</given-names></name>
<name><surname>Ramwell</surname><given-names>P</given-names></name>
<name><surname>Penhos</surname><given-names>J</given-names></name>
</person-group>. <article-title>Sexual differentiation of arachidonate toxicity in mice</article-title>. <source>J Pharmacol Exp Ther</source>. <year>1982</year>;<volume>222</volume>:<fpage>315</fpage>-<lpage>318</lpage>.</citation>
</ref>
<ref id="bibr18-0148607111414580">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Burr</surname><given-names>GO</given-names></name>
<name><surname>Burr</surname><given-names>MM</given-names></name>
</person-group>. <article-title>A new deficiency disease produced by the rigid exclusion of fat from the diet</article-title>. <source>J Biol Chem</source>. <year>1929</year>;<volume>82</volume>:<fpage>23</fpage>.</citation>
</ref>
<ref id="bibr19-0148607111414580">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alfin-Slater</surname><given-names>RB</given-names></name>
<name><surname>Aftergood</surname><given-names>L</given-names></name>
</person-group>. <article-title>Essential fatty acids reinvestigated</article-title>. <source>Physiol Rev</source>. <year>1968</year>;<volume>48</volume>:<fpage>758</fpage>-<lpage>784</lpage>.</citation>
</ref>
<ref id="bibr20-0148607111414580">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Calder</surname><given-names>PC</given-names></name>
</person-group>. <article-title>Dietary modification of inflammation with lipids</article-title>. <source>Proc Nutr Soc</source>. <year>2002</year>;<volume>61</volume>:<fpage>345</fpage>-<lpage>358</lpage>.</citation>
</ref>
<ref id="bibr21-0148607111414580">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ling</surname><given-names>PR</given-names></name>
<name><surname>Boyce</surname><given-names>P</given-names></name>
<name><surname>Bistrian</surname><given-names>BR</given-names></name>
</person-group>. <article-title>Role of arachidonic acid in the regulation of the inflammatory response in TNF-alpha-treated rats</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1998</year>;<volume>22</volume>:<fpage>268</fpage>-<lpage>275</lpage>.</citation>
</ref>
<ref id="bibr22-0148607111414580">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jensen</surname><given-names>CL</given-names></name>
<name><surname>Prager</surname><given-names>TC</given-names></name>
<name><surname>Fraley</surname><given-names>JK</given-names></name>
<name><surname>Chen</surname><given-names>H</given-names></name>
<name><surname>Anderson</surname><given-names>RE</given-names></name>
<name><surname>Heird</surname><given-names>WC</given-names></name>
</person-group>. <article-title>Effect of dietary linoleic/alpha-linolenic acid ratio on growth and visual function of term infants</article-title>. <source>J Pediatr</source>. <year>1997</year>;<volume>131</volume>:<fpage>200</fpage>-<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr23-0148607111414580">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wainwright</surname><given-names>PE</given-names></name>
<name><surname>Jalali</surname><given-names>E</given-names></name>
<name><surname>Mutsaers</surname><given-names>LM</given-names></name>
<name><surname>Bell</surname><given-names>R</given-names></name>
<name><surname>Cvitkovic</surname><given-names>S</given-names></name>
</person-group>. <article-title>An imbalance of dietary essential fatty acids retards behavioral development in mice</article-title>. <source>Physiol Behav</source>. <year>1999</year>;<volume>66</volume>:<fpage>833</fpage>-<lpage>839</lpage>.</citation>
</ref>
<ref id="bibr24-0148607111414580">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wainwright</surname><given-names>PE</given-names></name>
<name><surname>Xing</surname><given-names>HC</given-names></name>
<name><surname>Mutsaers</surname><given-names>L</given-names></name>
<name><surname>McCutcheon</surname><given-names>D</given-names></name>
<name><surname>Kyle</surname><given-names>D</given-names></name>
</person-group>. <article-title>Arachidonic acid offsets the effects on mouse brain and behavior of a diet with a low (n-6):(n-3) ratio and very high levels of docosahexaenoic acid</article-title>. <source>J Nutr</source>. <year>1997</year>;<volume>127</volume>:<fpage>184</fpage>-<lpage>193</lpage>.</citation>
</ref>
<ref id="bibr25-0148607111414580">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brossard</surname><given-names>N</given-names></name>
<name><surname>Croset</surname><given-names>M</given-names></name>
<name><surname>Pachiaudi</surname><given-names>C</given-names></name>
<name><surname>Riou</surname><given-names>JP</given-names></name>
<name><surname>Tayot</surname><given-names>JL</given-names></name>
<name><surname>Lagarde</surname><given-names>M</given-names></name>
</person-group>. <article-title>Retroconversion and metabolism of [13C]22:6n-3 in humans and rats after intake of a single dose of [13C]22:6n-3-triacylglycerols</article-title>. <source>Am J Clin Nutr</source>. <year>1996</year>;<volume>64</volume>:<fpage>577</fpage>-<lpage>586</lpage>.</citation>
</ref>
<ref id="bibr26-0148607111414580">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hempenius</surname><given-names>RA</given-names></name>
<name><surname>Van Delft</surname><given-names>JM</given-names></name>
<name><surname>Prinsen</surname><given-names>M</given-names></name>
<name><surname>Lina</surname><given-names>BA</given-names></name>
</person-group>. <article-title>Preliminary safety assessment of an arachidonic acid-enriched oil derived from Mortierella alpina: summary of toxicological data</article-title>. <source>Food Chem Toxicol</source>. <year>1997</year>;<volume>35</volume>:<fpage>573</fpage>-<lpage>581</lpage>.</citation>
</ref>
<ref id="bibr27-0148607111414580">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Javid</surname><given-names>PJ</given-names></name>
<name><surname>Greene</surname><given-names>AK</given-names></name>
<name><surname>Garza</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>The route of lipid administration affects parenteral nutrition-induced hepatic steatosis in a mouse model</article-title>. <source>J Pediatr Surg</source>. <year>2005</year>;<volume>40</volume>:<fpage>1446</fpage>-<lpage>1453</lpage>.</citation>
</ref>
<ref id="bibr28-0148607111414580">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wilson</surname><given-names>MD</given-names></name>
<name><surname>Blake</surname><given-names>WL</given-names></name>
<name><surname>Salati</surname><given-names>LM</given-names></name>
<name><surname>Clarke</surname><given-names>SD</given-names></name>
</person-group>. <article-title>Potency of polyunsaturated and saturated fats as short-term inhibitors of hepatic lipogenesis in rats</article-title>. <source>J Nutr</source>. <year>1990</year>;<volume>120</volume>:<fpage>544</fpage>-<lpage>552</lpage>.</citation>
</ref>
<ref id="bibr29-0148607111414580">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Attie</surname><given-names>AD</given-names></name>
<name><surname>Krauss</surname><given-names>RM</given-names></name>
<name><surname>Gray-Keller</surname><given-names>MP</given-names></name>
<etal/>
</person-group>. <article-title>Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia</article-title>. <source>J Lipid Res</source>. <year>2002</year>;<volume>43</volume>:<fpage>1899</fpage>-<lpage>1907</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>